$MTSI

Daly Stephen G sold $38K of MTSI

Daly Stephen G (President and CEO) sold 100 shares of MACOM Technology Solutions Holdings, Inc. (MTSI) at $382.60 on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Daly Stephen G
Published Jun 2, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 8:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MTSI
Neutral
medium confidence
Mentioned
$MTSI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MTSINeutralLow
01

Why it matters

The disclosed sale could marginally influence sentiment, but the presence of a pre-arranged 10b5-1 plan typically reduces the informational content for trading decisions.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no evidence of new fundamentals in the filing.

03

What to watch

The article provides only the sale size and remaining holdings, not whether other insiders or institutions changed positions around the same time.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/late day (2026-06-02 20:42 UTC) for today’s tape review.

Background

The article is an SEC Form 4 insider transaction disclosure for MACOM Technology Solutions Holdings, Inc. (MTSI).

Company-level read

Ticker impact

$MTSINeutralMedium confidence
Context

SEC Form 4 shows MTSI CEO Stephen G. Daly sold $38.3K of shares via a pre-arranged 10b5-1 plan on May 29.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a routine insider transaction with a stated pre-arranged 10b5-1 plan and small dollar value relative to typical market capitalization.

Market effects

Minimal; this is company-specific insider disclosure with no stated operational or guidance change.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be largely mechanical and not a meaningful negative signal.

Key entities

  • MACOM Technology Solutions Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Stephen G. Daly

    President and CEO who sold 100 shares at $382.60 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MCHPMed

Analog Semiconductors Stocks Q2 Teardown: Microchip Technology (NASDAQ:MCHP) Vs The Rest

Microchip Technology (MCHP) and 13 other analog semiconductor stocks reported Q2 earnings, with revenues beating estimates by 1.8% and next quarter's guidance 4.9% above. MCHP reported $1.48B revenue, up 38% YoY, and its stock is up 2.4%. Monolithic Power Systems (MPWR) had the strongest performance, while Himax (HIMX) had the slowest growth. The sector's stocks are down 2.2% on average since earnings.

$NVDAMed

BMO starts chip stocks coverage: Here are its preferred picks

BMO Capital Markets initiated coverage of semiconductor and quantum computing sectors, favoring AI-exposed and analog chipmakers. Nvidia (top pick) received an Outperform rating and $340 target, with expected revenue growth of 84% and 50% in FY27 and 2028. Other picks include Broadcom, Micron, AMD, Marvell, Semtech, Analog Devices, Microchip, and Impinj. BMO predicts a memory market supercycle and AI-driven capex growth.

$MTSIMed

Why MACOM (MTSI) Stock Is Trading Up Today

MACOM Technology Solutions (MTSI) shares rose about 3% to $326.57 after Benchmark reinstated coverage with a Buy rating and a $375 price target, according to TipRanks. Benchmark said roughly two-thirds of revenue comes from higher-growth end markets. The article also cites Bloomberg reporting Anthropic’s Q2 revenue rose more than 14-fold to over $11.5B.